Exodus Point Capital Management, LP T Scan Therapeutics, Inc. Call Options Transaction History
Exodus Point Capital Management, LP
- $13.1 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding TCRX
# of Institutions
66Shares Held
29.3MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$35.4 Million1.13% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$27.6 Million0.06% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$21.2 Million0.71% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$19.7 Million0.28% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$14.8 Million9.65% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $134M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...